"From Kolhapur to ₹2,367 target—Metropolis is on the move!"

🧪 Q2 FY2026 Highlights - Consolidated Revenue: Up 23% YoY, led by TruHealth Wellness (+25%) and Specialty Diagnostics (+36%). - B2C Revenue: Grew 16% YoY; B2B Revenue: Jumped 34% YoY, especially in core diagnostics. - EBITDA Margins: Improved YoY and QoQ due to operating leverage and better product mix. - Standalone Revenue: Up 12% YoY, supported by higher patient volumes and realizations. - Acquisition: Ambika Pathology Lab (Kolhapur) added regional reach and productivity. - Cash Position: Debt-free with ₹55 crore net cash surplus. 📈 Stock Impact - Price Action: Stock rose 7.65% intraday, closed 3.84% higher at ₹2,073 on NSE. - Valuation: Analysts revised rating from Neutral to Buy, with a target price of ₹2,367. - Market Sentiment: Positive due to margin expansion and network growth, but cautious on competitive pricing pressures. 🔍 Investor Watchouts - Margin Sustainability: High margins in wellness and specialty segments must hold amid rising competition. - B2C vs B2B Balance: Continued B2C growth is key for profitability; B2B growth is margin-dilutive. - Network Expansion: Target to grow from 700 to 1,000 towns in 12–18 months—execution risk exists. - Inorganic Growth Strategy: Focused on acquiring leaders in B2C-heavy regions and advanced diagnostics capabilities.